Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1
Authors:
- 8 November 2018
- journal article
- research article
- Published by Springer Nature in In Vitro Cellular & Developmental Biology - Animal
- Vol. 55 (1) , 62-73
Abstract
Dermatofibrosarcoma protuberans (DFSP) is a common type of dermal sarcoma, characterized by the presence of the unique collagen type I alpha 1 chain (COL1A1)-PDGFB translocation, which causes constitutive activation of the platelet-derived growth factor β (PDGFB) signaling pathway. Patients with DFSP exhibit frequent local recurrence, and novel therapeutic approaches are required to achieve better clinical outcomes. Patient-derived cancer cell lines are essential in the preclinical research. Here, we established novel patient-derived DFSP cell lines from two patients with DFSP and designated these cell lines NCC-DFSP1-C1 and NCC-DFSP2-C1. Tumors of the two patients with DFSP had COL1A1-PDGFB translocations with distinct COL1A1 breakpoints, e.g., in exons 33 and 15, and the translocations were preserved in the established cell lines. NCC-DFSP1-C1 and NCC-DFSP2-C1 cells exhibited similar morphology and limited capability of proliferation in vitro, forming spheroids when seeded on low-attachment tissue culture plates. In contrast, NCC-DFSP1-C1 cells had considerably higher invasive capability than NCC-DFSP2-C1 cells. Overall proteome contents were similar between NCC-DFSP1-C1 and NCC-DFSP2-C1 cells. Notably, in vitro screening studies identified anticancer drugs that showed antiproliferative effects at considerably low concentrations in the DFSP cell lines. Bortezomib, mitoxantrone, ponatinib, and romidepsin were more cytotoxic to NCC-DFSP1-C1 cells than to NCC-DFSP2-C1 cells. These cell lines will be useful tools for developing novel therapeutic strategies to treat DFSP.Keywords
Funding Information
- National Cancer Center Research and Development Fund (29-A-2)
This publication has 33 references indexed in Scilit:
- Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database reportCancer Medicine, 2014
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberansLaboratory Investigation, 2007
- Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002Journal of the American Academy of Dermatology, 2007
- Outcomes of surgery for dermatofibrosarcoma protuberansEuropean Journal of Surgical Oncology, 2004
- Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberansInternational Journal of Cancer, 2002
- Growth-inhibitory effect of STI571 on cells transformed by theCOL1A1/PDGFB rearrangementInternational Journal of Cancer, 2001
- Dermatofibrosarcoma protuberansCancer, 2000
- Dermatofibrosarcoma protuberans metastasizing to lymph nodes: A case report and review of literatureJournal of Surgical Oncology, 1999
- Dermatofibrosarcoma protuberansJournal of the American Academy of Dermatology, 1996